Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVISTA vs FARESTON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective estrogen receptor modulator (SERM) that binds to estrogen receptors, acting as an agonist in bone and antagonist in breast and uterine tissues.
Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.
Treatment and prevention of osteoporosis in postmenopausal women,Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis,Reduction in risk of invasive breast cancer in postmenopausal women at high risk for breast cancer
FDA-approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors,Off-label: treatment of advanced breast cancer in premenopausal women in combination with ovarian suppression
60 mg orally once daily.
60 mg orally once daily.
Terminal elimination half-life is approximately 32.5 hours (range 27-39 hours) for raloxifene and its glucuronide conjugates; clinically relevant for once-daily dosing.
The terminal elimination half-life of toremifene is approximately 5 days (range 2-10 days). The half-life of its main metabolite, N-desmethyltoremifene, is about 11 days. This long half-life supports once-daily dosing.
Extensively metabolized in the liver via glucuronidation (UGT1A1, UGT1A8, UGT1A9) and CYP3A4-mediated oxidation.
Primarily hepatic via CYP3A4 and CYP1A2; undergoes glucuronidation; active metabolite N-desmethyltoremifene
Raloxifene undergoes extensive glucuronidation; <0.1% excreted unchanged in urine. Approximately 95% is excreted in feces over 5 days (primarily as glucuronide conjugates). Renal elimination of unchanged drug is negligible (<0.1%).
FARESTON (toremifene) is extensively metabolized in the liver. Excretion is primarily fecal (approximately 70%) with renal excretion accounting for less than 10% of the dose as unchanged drug and metabolites.
>95% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
Toremifene is >99% bound to plasma proteins, primarily albumin.
Apparent Vd/F is approximately 1000-1500 L (not weight-based; extensive tissue distribution).
The apparent volume of distribution (Vd) is approximately 580 L (about 8 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Absolute oral bioavailability is approximately 2% due to extensive first-pass glucuronidation; systemic exposure is dose-proportional.
Oral bioavailability of toremifene is not precisely determined but is estimated to be nearly 100% based on absorption and first-pass metabolism studies.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min.
Contraindicated in patients with Child-Pugh Class B or C hepatic impairment. No specific dose adjustment recommended for Child-Pugh Class A, but use with caution.
Contraindicated in Child-Pugh class C; use with caution in class A or B without specific dose reduction guidelines.
Safety and efficacy not established in pediatric patients; no recommended dose.
Safety and efficacy not established; no recommended dose.
No specific dose adjustment required; use standard adult dosing. Consider increased risk of venous thromboembolism and stroke in elderly women.
No specific dose adjustment; monitor renal function and electrolyte balance.
Increased risk of venous thromboembolism (VTE) and death from stroke. Not for use in women with active or history of VTE, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. Not for use in women with atrial fibrillation or other conditions that increase risk of stroke.
None
Risk of VTE; discontinue if VTE occurs. Risk of stroke; discontinue if stroke occurs or for prolonged immobilization. May increase risk of endometrial cancer; monitor for abnormal bleeding. Not for premenopausal women. Use with caution in patients with hepatic impairment or cholestasis. May increase triglycerides; monitor in patients with history of hypertriglyceridemia.
QT interval prolongation,Hypercalcemia in patients with bone metastases,Endometrial hyperplasia/cancer risk,Thromboembolic events,Ocular toxicity (dose-dependent retinopathy),Tumor flare
Active or history of VTE, pregnancy, women who may become pregnant, lactation, hypersensitivity to raloxifene, or any component of the formulation.
Hypersensitivity to toremifene or any excipients,History of thromboembolic disease,Pre-existing endometrial hyperplasia,Patients with long QT syndrome or concurrent use of QT-prolonging drugs
Avoid grapefruit and grapefruit juice as they may increase raloxifene levels. No other significant food interactions.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition, which can increase toremifene levels and risk of adverse effects. No other significant food interactions known. Take with or without food.
Pregnancy Category X. Raloxifene is contraindicated in pregnancy. In animal studies, raloxifene caused fetal abnormalities including skeletal malformations and cardiovascular defects. Human data are unavailable due to contraindication; use in pregnancy may cause fetal harm.
Pregnancy Category D. First trimester: Risk of fetal harm, including spontaneous abortion and congenital malformations (e.g., craniofacial, cardiac). Second and third trimesters: Potential for fetal hypothalamic-pituitary-gonadal axis disruption, ambiguous genitalia in female fetuses, and other adverse effects based on animal studies.
Raloxifene is excreted in rat milk; no human data available. The M/P ratio is unknown. Due to potential adverse effects on the infant, breastfeeding is not recommended during therapy.
Not recommended during breastfeeding. Toremifene may be excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants, including hormonal disruption.
No dosing adjustments are applicable as raloxifene is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy do not inform dose modifications due to the contraindication.
No established dose adjustments; use contraindicated in pregnancy. Pharmacokinetic changes (increased volume of distribution, altered clearance) may require empirical dose reduction if used inadvertently, but no specific guidelines exist. Avoid use.
Monitor for venous thromboembolism; avoid in patients with active or history of VTE. May increase risk of stroke in postmenopausal women with coronary heart disease. No significant effect on breast cancer incidence. Administer with caution in hepatic impairment. Discontinue prior to prolonged immobilization or surgery.
FARESTON (toremifene) is a selective estrogen receptor modulator (SERM) used for metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors. Unlike tamoxifen, toremifene has a longer half-life (about 5 days) and may have a lower risk of thromboembolic events. Monitor liver function tests regularly due to potential hepatotoxicity. Prolongation of QT interval has been reported; avoid in patients with pre-existing QTc prolongation or with other QT-prolonging drugs. Use with caution in patients with endometrial hyperplasia or history of thromboembolic disease.
Take once daily with or without food.,Report any signs of blood clots (leg pain/swelling, sudden chest pain, shortness of breath).,May cause hot flashes, leg cramps, or flu-like symptoms.,Avoid pregnancy; not indicated for premenopausal women.,Requires adequate calcium and vitamin D intake.
Take this medication exactly as prescribed, usually once daily with or without food.,You may experience hot flashes, nausea, or sweating; these are common and usually manageable.,Report any unusual vaginal bleeding, discharge, or pelvic pain to your doctor immediately.,Watch for signs of blood clots such as leg pain/swelling, sudden chest pain, or shortness of breath.,Avoid grapefruit and grapefruit juice while on this medication as they may increase side effects.,Use non-hormonal contraception if you are still able to become pregnant; toremifene can harm a fetus.,Do not stop or change your dose without consulting your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVISTA vs FARESTON, answered by our medical review team.
EVISTA is a Selective Estrogen Receptor Modulator that works by Selective estrogen receptor modulator (SERM) that binds to estrogen receptors, acting as an agonist in bone and antagonist in breast and uterine tissues.. FARESTON is a Selective Estrogen Receptor Modulator that works by Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVISTA and FARESTON depend on the specific clinical indication. These are both Selective Estrogen Receptor Modulator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVISTA is: 60 mg orally once daily.. The standard adult dose of FARESTON is: 60 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVISTA and FARESTON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVISTA is classified as Category C. Pregnancy Category X. Raloxifene is contraindicated in pregnancy. In animal studies, raloxifene caused fetal abnormalities including skeletal malformations and cardiovascular defec. FARESTON is classified as Category C. Pregnancy Category D. First trimester: Risk of fetal harm, including spontaneous abortion and congenital malformations (e.g., craniofacial, cardiac). Second and third trimesters: P. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.